Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

02/04/2026

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗮𝘁 𝘁𝗵𝗲 #𝗣𝗠𝗠𝗣 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲, 𝗳𝗼𝗰𝘂𝘀𝗶𝗻𝗴 𝗼𝗻 𝗣𝗢𝗟𝗘 𝗶𝗻 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿!
📅 Monday 13 April, 10:30 AM (CEST)
📍 PMMP Conference, Naples, Italy
🎤 Dr. Elisa Melucci (IFO – Istituto Regina Elena, Rome)*
🗣️ Italian

𝗚𝗲𝘁 𝗺𝗼𝗿𝗲 𝗶𝗻𝗳𝗼 👉https://educational.siapecservizi.it/images/congressi/279/programma.pdf

*𝘗𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘪𝘰𝘯 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘦𝘥 𝘣𝘺 𝘉𝘪𝘰𝘤𝘢𝘳𝘵𝘪𝘴.

01/04/2026

𝐖𝐞 𝐥𝐨𝐯𝐞 𝐚 𝐠𝐨𝐨𝐝 𝐀𝐩𝐫𝐢𝐥 𝐅𝐨𝐨𝐥'𝐬 𝐣𝐨𝐤𝐞, 𝐛𝐮𝐭 𝐰𝐡𝐞𝐧 𝐢𝐭 𝐜𝐨𝐦𝐞𝐬 𝐭𝐨 𝐈𝐝𝐲𝐥𝐥𝐚™, 𝐰𝐞’𝐫𝐞 𝐧𝐨𝐭 𝐟𝐨𝐨𝐥𝐢𝐧𝐠 𝐚𝐫𝐨𝐮𝐧𝐝 😉
With Idylla™, there are no tricks, no complexities, and no room for error — just fast, accurate, and fully automated testing that delivers reliable results ⏱️

👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=0104_meet-idylla

31/03/2026

As comes to an end, we must not forget that the fight against CRC continues every day 💪

At Biocartis, we are dedicated to delivering fast & accurate molecular diagnostics to enable improvement of mCRC patient outcomes*. With Idylla™, biomarkers like , , , and are detected in ⏱️ONLY 3 HOURS⏱️, enabling immediate decisions for immunotherapy and targeted therapies. This rapid turnaround time ✔️reduces delays, ✔️alleviates patient anxiety, and ✔️ensures patients immediately get personalized care.
𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 👀 https://www.biocartis.com/en/oncology/for-oncologists/idylla-for-colorectal-cancer?utm_source=facebook&utm_medium=social&utm_campaign=3103_idylla-for-colorectal-cancer

💪 Let’s keep the momentum going beyond March and continue striving for better outcomes for every patient.

*The content of this post only applies to the Idylla™ KRAS & NRAS-BRAF Tests which are CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. These Tests are not available in the US, but are for Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ CDx MSI Test is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) (A0220/6) and approved in the US under P250005 (A0220/6). Idylla™ MSI Test is CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC (A0100/6) and cleared in the US under K211181 for Lynch Syndrome (A0160/6).

25/03/2026

📣 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 (𝗜𝗩𝗗𝗥*)
✔️ Companion diagnostic (𝗖𝗗𝘅) to identify adult patients with MSI-H mCRC who may benefit from treatment with 𝗢𝗣𝗗𝗜𝗩𝗢® (nivolumab) + 𝗬𝗘𝗥𝗩𝗢𝗬® (ipilimumab)
✔️ Sample to result in ~𝟭𝟱𝟬 𝗺𝗶𝗻 without the need for sample batching
✔️ Concordance rate of 𝟵𝟴.𝟱𝟳% against OncoMate™ MSI Dx Analysis System
✔️ Directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, 𝗻𝗼 𝗽𝗮𝗶𝗿𝗲𝗱 tissue samples needed

𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-cdx-msi-test

*𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘮𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴. 𝘖𝘗𝘋𝘐𝘝𝘖® 𝘢𝘯𝘥 𝘠𝘌𝘙𝘝𝘖𝘠® 𝘢𝘳𝘦 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬𝘴 𝘰𝘧 𝘉𝘳𝘪𝘴𝘵𝘰𝘭-𝘔𝘺𝘦𝘳𝘴 𝘚𝘲𝘶𝘪𝘣𝘣 𝘊𝘰𝘮𝘱𝘢𝘯𝘺.

24/03/2026

📢 𝗣𝗥𝗘𝗦𝗦 𝗡𝗘𝗪𝗦: 𝗕𝗶𝗼𝗰𝗮𝗿𝘁𝗶𝘀 𝘁𝗼 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲 𝘄𝗶𝘁𝗵 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗼𝗹𝗹𝗲𝗴𝗲 𝗼𝗳 𝗪𝗶𝘀𝗰𝗼𝗻𝘀𝗶𝗻 𝗼𝗻 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗚𝗲𝗻𝗲 𝗦𝗶𝗴𝗻𝗮𝘁𝘂𝗿𝗲𝘀
We’re excited to announce that we have entered into a 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 with the Medical College of Wisconsin to provide laboratory expertise and archived samples for the development of a 𝗿𝗮𝗽𝗶𝗱, 𝘀𝗮𝗺𝗽𝗹𝗲-𝘁𝗼-𝗮𝗻𝘀𝘄𝗲𝗿 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗴𝗲𝗻𝗲 𝘀𝗶𝗴𝗻𝗮𝘁𝘂𝗿𝗲 𝘁𝗲𝘀𝘁.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/ettYgXtg

𝘛𝘩𝘦 𝘵𝘦𝘴𝘵 𝘪𝘯 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘶𝘴𝘦.

24/03/2026

🙌 𝗪𝗲'𝗿𝗲 𝗵𝗮𝘃𝗶𝗻𝗴 𝗮 𝗴𝗿𝗲𝗮𝘁 𝘁𝗶𝗺𝗲 𝗮𝘁 𝗨𝗦𝗖𝗔𝗣 𝟮𝟬𝟮𝟲 in San Antonio, TX, US!
Come say hi to Joe and Cedric at 𝗯𝗼𝗼𝘁𝗵 𝟳𝟱𝟱 to learn more about getting your molecular biomarker results in only 3 hours on the fully automated Idylla™ Platform⏱️

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eD9-Kp3N

22/03/2026

📅 𝟐𝟐 𝐌𝐚𝐫𝐜𝐡 𝐢𝐬 𝐋𝐲𝐧𝐜𝐡 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐃𝐚𝐲!
Lynch Syndrome is a rare condition that increases the risk of developing certain cancers, such as colorectal cancer.

💡 Did you know that 1 in 279 people have Lynch Syndrome, meaning they have a 20-80% lifetime risk of developing colorectal cancer?*

👉 The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭 (IVD**) serves as an aid to identify those colorectal cancer patients who should undergo further diagnostic testing for Lynch Syndrome.
Read more here 👀 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-msi-test?utm_source=facebook&utm_medium=social&utm_campaign=2203_idylla-msi-test

*Win, A.K. et al. (2016) Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 26(3), 404–412.
** Idylla™ MSI Test is CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC and is cleared in the US under K211181 for Lynch Syndrome.

20/03/2026

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗨𝗦𝗖𝗔𝗣 𝟮𝟬𝟮𝟲!
📅 21-26 March |📍Booth 755 | 🗺️ San Antonio, TX, USA

Stop by booth 755 and learn more about getting your molecular biomarker results in only 3 hours on the fully automated Idylla™ Platform⏱️
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eD9-Kp3N

18/03/2026

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf

*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

The content of this post is only applicable to Idylla™ EGFR Mutation Test and Idylla™ GeneFusion Panel which are CE-marked in Europe. Idylla™ EGFR Mutation Assay and Idylla™ GeneFusion Assay are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

16/03/2026

📣This 𝐂𝐑𝐂 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, we want to spotlight how essential the use of standardized, validated MSI testing is for guiding therapy in mCRC.

The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐂𝐃𝐱 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭 delivers:
• Fully automated, sample-to-result workflow
• ~150 min. TAT with

13/03/2026

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗨𝗦𝗖𝗔𝗣 𝟮𝟬𝟮𝟲!
📅 21-26 March |📍Booth 755 | 🗺️ San Antonio, TX, USA

Stop by booth 755 and learn more about getting your molecular biomarker results in only 3 hours on the fully automated Idylla™ Platform⏱️

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en-US/news-events/events/uscap-2026

13/03/2026

We're attending the 𝗢𝗚𝗣𝗮𝘁𝗵 𝗦𝗽𝗿𝗶𝗻𝗴 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲!
📅 13-14 March | 🗺️ Vienna, Austria

Come and say hi! Dr. Manfred & Dr. Edgar are eager to show you Idylla™, a fully automated platform that generates molecular biomarker results in only 3 hours⏱️
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/gh9nKbMA

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.